Journal of the American College of Cardiology

Journal Information
ISSN / EISSN : 07351097 / 15583597
Current Publisher: Elsevier BV (10.1016)
Total articles ≅ 86,094
Google Scholar h5-index: 180
Current Coverage
SCOPUS
PUBMED
MEDLINE
MEDICUS
SCIE
LOCKSS
Archived in
SHERPA/ROMEO
EBSCO
Filter:

Latest articles in this journal

David R. Holmes, Mohamad Alkhouli
Journal of the American College of Cardiology, Volume 75, pp 2738-2743; doi:10.1016/j.jacc.2020.03.066

Mark Trinder, Maria L. DeCastro, Hawmid Azizi, Luba Cermakova, Linda M. Jackson, Jiri Frohlich, G.B. John Mancini, Gordon A. Francis, Liam R. Brunham
Journal of the American College of Cardiology, Volume 75, pp 2682-2693; doi:10.1016/j.jacc.2020.03.065

The publisher has not yet granted permission to display this abstract.
Jasmine Grewal, Samuel C. Siu, Terry Lee, Rohan D’Souza, Merav Dvir, Joel Singer, Valerie Rychel, Marla Kiess, Mathew Sermer, Candice K. Silversides
Journal of the American College of Cardiology, Volume 75, pp 2751-2752; doi:10.1016/j.jacc.2020.03.068

Umair Khalid, Lucas N. Marzec, Nicholas Mantini, Spero M. Manson, Gheorghe Doros, Christopher P. Cannon, Yang Song, Liyan Dong, Jonathan C. Hsu, Mark Y. Jeong, et al.
Journal of the American College of Cardiology, Volume 75, pp 2749-2750; doi:10.1016/j.jacc.2020.03.069

Vivek Narayan, Elizabeth W. Thompson, Biniyam Demissei, Jennifer E. Ho, James L. Januzzi, Bonnie Ky
Journal of the American College of Cardiology, Volume 75, pp 2726-2737; doi:10.1016/j.jacc.2020.03.067

The publisher has not yet granted permission to display this abstract.
Carolyn Y. Ho, Matthew E. Mealiffe, Richard G. Bach, Mondira Bhattacharya, Lubna Choudhury, Jay M. Edelberg, Sheila M. Hegde, Daniel Jacoby, Neal K. Lakdawala, Steven J. Lester, et al.
Journal of the American College of Cardiology, Volume 75, pp 2649-2660; doi:10.1016/j.jacc.2020.03.064

Abstract:
Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. By altering the contractile mechanics of the cardiomyocyte, myosin inhibitors have the potential to modify pathophysiology and improve symptoms associated with HCM. MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the safety and efficacy of mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, in nHCM. The MAVERICK-HCM trial was a multicenter, double-blind, placebo-controlled, dose-ranging phase II study in adults with symptomatic nHCM (New York Heart Association functional class II/III), left ventricular ejection fraction (LVEF) ≥55%, and N-terminal pro−B-type natriuretic peptide (NT-proBNP) ≥300 pg/ml. Participants were randomized 1:1:1 to mavacamten at a pharmacokinetic-adjusted dose (targeting plasma levels of 200 or 500 ng/ml), or placebo for 16 weeks, followed by an 8-week washout. Initial dose was 5 mg daily with 1 dose titration at week 6. Fifty-nine participants were randomized (19, 21, 19 patients to 200 ng/ml, 500 ng/ml, placebo, respectively). Their mean age was 54 years, and 58% were women. Serious adverse events occurred in 10% of participants on mavacamten and in 21% participants on placebo. Five participants on mavacamten had reversible reduction in LVEF ≤45%. NT-proBNP geometric mean decreased by 53% in the pooled mavacamten group versus 1% in the placebo group, with geometric mean differences of −435 and −6 pg/ml, respectively (p = 0.0005). Cardiac troponin I (cTnI) geometric mean decreased by 34% in the pooled mavacamten group versus a 4% increase in the placebo group, with geometric mean differences of −0.008 and 0.001 ng/ml, respectively (p = 0.009). Mavacamten, a novel myosin inhibitor, was well tolerated in most subjects with symptomatic nHCM. Furthermore, treatment was associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress. These results set the stage for future studies of mavacamten in this patient population using clinical parameters, including LVEF, to guide dosing. (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy [MAVERICK-HCM]; NCT03442764)
Myeong-Ki Hong, Seung-Yul Lee
Journal of the American College of Cardiology, Volume 75, pp 2679-2681; doi:10.1016/j.jacc.2020.04.005

The publisher has not yet granted permission to display this abstract.
Journal of the American College of Cardiology, Volume 75; doi:10.1016/s0735-1097(20)35232-3

Cynthia Rucinski, Annika Winbo, Luciana Marcondes, Nikki Earle, Martin Stiles, Rachael Stiles, Darren Hooks, Kate Neas, Ian Hayes, Jackie Crawford, et al.
Journal of the American College of Cardiology, Volume 75, pp 2698-2707; doi:10.1016/j.jacc.2020.04.004

The publisher has not yet granted permission to display this abstract.
Jane E. Wilcox, Elizabeth M. McNally
Journal of the American College of Cardiology, Volume 75, pp 2661-2663; doi:10.1016/j.jacc.2020.04.017

The publisher has not yet granted permission to display this abstract.
Back to Top Top